Hostname: page-component-6766d58669-6mz5d Total loading time: 0 Render date: 2026-05-23T10:41:18.499Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis

Published online by Cambridge University Press:  31 October 2024

Sabrina Wong ,
Gia Han Le ,
Angela T.H. Kwan ,
Kayla M. Teopiz ,
Taeho Greg Rhee ,
Roger Ho ,
Joshua D. Rosenblat ,
Rodrigo Mansur Open the ORCID record for Rodrigo Mansur [Opens in a new window]  and
Roger S. McIntyre Open the ORCID record for Roger S. McIntyre [Opens in a new window]
Sabrina Wong
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada
Gia Han Le
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada
Angela T.H. Kwan
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
Kayla M. Teopiz
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, ON, Canada
Taeho Greg Rhee
Affiliation:
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA
Roger Ho
Affiliation:
Department of Psychiatry, University of Toronto, Toronto, ON, Canada Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, Singapore Division of Life Science (LIFS), Hong Kong University of Science and Technology, Hong Kong, China
Joshua D. Rosenblat
Affiliation:
Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Rodrigo Mansur
Affiliation:
Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Roger S. McIntyre*
Affiliation:
Department of Psychiatry, University of Toronto, Toronto, ON, Canada
*
Corresponding author: Roger S. McIntyre; Email: roger.mcintyre@bcdf.org.
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Postpartum depression (PPD), now referred to as perinatal depression, is a prevalent and debilitating mood disorder that reduces health-related quality of life (HRQoL) and psychosocial functioning. Esketamine, which is efficacious in adults with treatment-resistant depression and individuals with depression and suicidality, is also analgesic in pain management during childbirth labour. Herein, we investigate the efficacy of prophylactic esketamine in reducing the incidence of PPD.

Methods

We performed a systematic review (i.e., PubMed, Scopus, and Ovid databases; inception to January 22, 2024) of randomized controlled trials that investigated the use of esketamine for PPD. We delimited our search to studies that prespecified the prevention of PPD with esketamine as the primary outcome. A meta-analysis was performed on PPD incidence rates using a random effects model.

Results

Our analysis consisted of seven studies that met our eligibility criteria. We found that esketamine was significantly associated with a decreased incidence of PPD diagnosis within one week of childbirth (OR = 0.30, 95% CI = [0.15, 0.60], p = 0.0047). We also observed that esketamine was significantly associated with a decreased incidence of PPD diagnosis between 4 to 6 weeks post-delivery (OR = 0.33, 95% CI = [0.18, 0.59], p = 0.0034).

Conclusion

Our results indicate that esketamine may have preventive antidepressant effects during the postpartum period. The aforementioned points have both mechanistic and clinically meaningful implications for the treatment of PPD.

Keywords

esketaminepostpartum depression (PPD)perinatal depressionEdinburgh perinatal depression scalemajor depressive disorder (MDD)MDD preventiontreatment resistant depression (TRD)

Information

Type
Review
Information
CNS Spectrums , Volume 29 , Issue 5 , October 2024 , pp. 326 - 334
Copyright
© The Author(s), 2024. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

This article has been updated since it was originally published. A notice detailing this has been published.

References

Mughal, S, Azhar, Y, Siddiqui, W. Postpartum Depression. In: StatPearls. StatPearls Publishing; 2024. Accessed February 8, 2024. http://www.ncbi.nlm.nih.gov/books/NBK519070/ Google Scholar
Freeman, MP. Perinatal Depression: Recommendations for Prevention and the Challenges of Implementation. JAMA. 2019;321(6):550–552. doi:10.1001/jama.2018.21247 CrossRefGoogle ScholarPubMed
Psychiatry.org - What is Perinatal Depression (formerly Postpartum)? Accessed February 8, 2024. https://www.psychiatry.org/patients-families/peripartum-depression/what-is-peripartum-depression#section_4 Google Scholar
Kroska, EB, Stowe, ZN. Postpartum Depression: Identification and Treatment in the Clinic Setting. Obstetrics and Gynecology Clinics of North America. 2020;47(3):409–419. doi:10.1016/j.ogc.2020.05.001 CrossRefGoogle ScholarPubMed
Vanderkruik, R, Freeman, MP, Nonacs, R, et al. To screen or not to screen: Are we asking the right question? In response to considering de-implementation of universal perinatal depression screening. General Hospital Psychiatry. 2023;83:81–85. doi:10.1016/j.genhosppsych.2023.04.012 CrossRefGoogle ScholarPubMed
Desaunay, P, Eude, LG, Dreyfus, M, et al. Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses. Pediatr Drugs. 2023;25(3):247–265. doi:10.1007/s40272-023-00561-2 CrossRefGoogle ScholarPubMed
Kanes, S, Colquhoun, H, Gunduz-Bruce, H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. The Lancet. 2017;390(10093):480–489. doi:10.1016/S0140-6736(17)31264-3 CrossRefGoogle ScholarPubMed
Cha, DS, Kleine, N, Teopiz, KM, et al. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis. Expert Opinion on Pharmacotherapy. 2024;25(1):5–14. doi:10.1080/14656566.2023.2298340 CrossRefGoogle ScholarPubMed
Miuli, A, Pettorruso, M, Stefanelli, G, et al. Beyond the efficacy of transcranial magnetic stimulation in peripartum depression: A systematic review exploring perinatal safety for newborns. Psychiatry Research. 2023;326:115251 doi:10.1016/j.psychres.2023.115251 CrossRefGoogle ScholarPubMed
d’Andrea, G, Mancusi, G, Santovito, MC, et al. Investigating the Role of Maintenance TMS Protocols for Major Depression: Systematic Review and Future Perspectives for Personalized Interventions. J Pers Med. 2023;13(4):697 doi:10.3390/jpm13040697 CrossRefGoogle ScholarPubMed
McIntyre, RS, Alsuwaidan, M, Baune, BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394–412. doi:10.1002/wps.21120 CrossRefGoogle ScholarPubMed
Chen-Li, D, Lui, LMW, Rosenblat, JD, et al. Ketamine as potential treatment for postpartum depression: A narrative review. Ann Clin Psychiatry. 2022;34(4):264–274. doi:10.12788/acp.0082 CrossRefGoogle ScholarPubMed
Li, S, Zhou, W, Li, P, Lin, R. Effects of ketamine and esketamine on preventing postpartum depression after cesarean delivery: A meta-analysis. Journal of Affective Disorders. 2024;351:720–728. doi:10.1016/j.jad.2024.01.202 CrossRefGoogle ScholarPubMed
McIntyre, RS, Rosenblat, JD, Nemeroff, CB, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. AJP. 2021;178(5):383–399. doi:10.1176/appi.ajp.2020.20081251 CrossRefGoogle ScholarPubMed
Han, Y, Li, P, Miao, M, Tao, Y, Kang, X, Zhang, J. S-ketamine as an adjuvant in patient-controlled intravenous analgesia for preventing postpartum depression: a randomized controlled trial. BMC Anesthesiology. 2022;22(1):49 doi:10.1186/s12871-022-01588-7 CrossRefGoogle Scholar
Martinotti, G, Vita, A, Fagiolini, A, et al. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study). Journal of Affective Disorders. 2022;319:646–654. doi:10.1016/j.jad.2022.09.043 CrossRefGoogle Scholar
Chiappini, S, d’Andrea, G, De Filippis, S, et al. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. Eur Neuropsychopharmacol. 2023;74:15–21. doi:10.1016/j.euroneuro.2023.04.011 CrossRefGoogle Scholar
d’Andrea, G, Chiappini, S, McIntyre, RS, et al. Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group. The American Journal of Geriatric Psychiatry. 2023;31(12):1032–1041. doi:10.1016/j.jagp.2023.06.016 CrossRefGoogle ScholarPubMed
Ma, S, Dou, Y, Wang, W, et al. Association between esketamine interventions and postpartum depression and analgesia following cesarean delivery: a systematic review and meta-analysis. American Journal of Obstetrics & Gynecology MFM. 2024;6(3):101241 doi:10.1016/j.ajogmf.2023.101241 CrossRefGoogle ScholarPubMed
Page, MJ, McKenzie, JE, Bossuyt, PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71 doi:10.1136/bmj.n71 CrossRefGoogle ScholarPubMed
Sterne, JAC, Savović, J, Page, MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898 CrossRefGoogle ScholarPubMed
Higgins, JPT, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557 CrossRefGoogle ScholarPubMed
Balduzzi, S, Rücker, G, Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–160. doi:10.1136/ebmental-2019-300117 CrossRefGoogle Scholar
Ling, B, Zhu, Y, Yan, Z, et al. Effect of single intravenous injection of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial. BMC Pharmacology and Toxicology. 2023;24(1):66 doi:10.1186/s40360-023-00705-7 CrossRefGoogle ScholarPubMed
Liu, QR, Zong, QK, Ding, LL, et al. Effects of perioperative use of esketamine on postpartum depression risk in patients undergoing cesarean section: A randomized controlled trial. Journal of Affective Disorders. 2023;339:815–822. doi:10.1016/j.jad.2023.07.103 CrossRefGoogle ScholarPubMed
Shen, J, Song, C, Lu, X, et al. The effect of low-dose esketamine on pain and post-partum depression after cesarean section: A prospective, randomized, double-blind clinical trial. Frontiers in Psychiatry. 2023;13:1038379. Accessed February 8, 2024. 10.3389/fpsyt.2022.1038379 CrossRefGoogle ScholarPubMed
Wang, W, Ling, B, Zhao, H, et al. Effect of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial. BMC Anesthesiology. 2024;24(1):4 doi:10.1186/s12871-023-02377-6 CrossRefGoogle ScholarPubMed
Xu, S, Yang, J, Li, J, et al. Esketamine pretreatment during cesarean section reduced the incidence of postpartum depression: a randomized controlled trial. BMC Anesthesiology. 2024;24(1):20 doi:10.1186/s12871-023-02398-1 CrossRefGoogle Scholar
Yang, SQ, Zhou, YY, Yang, ST, et al. Effects of different doses of esketamine intervention on postpartum depressive symptoms in cesarean section women: A randomized, double-blind, controlled clinical study. Journal of Affective Disorders. 2023;339:333–341. doi:10.1016/j.jad.2023.07.007 CrossRefGoogle ScholarPubMed
Wolfson, P, Cole, R, Lynch, K, et al. The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites. Journal of Psychoactive Drugs. 2023;55(3):354–358. doi:10.1080/02791072.2022.2101903 CrossRefGoogle ScholarPubMed
Supplementary material: File

Wong et al. supplementary material

Wong et al. supplementary material
Download Wong et al. supplementary material(File)
File 338.4 KB